Anzeige
Mehr »
Montag, 02.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
156 Leser
Artikel bewerten:
(1)

Innovaccer Receives Frost & Sullivan's 2026 United States New Product Innovation Recognition for Excellence in AI-Driven Patient Access Solutions

The recognition highlights Innovaccer's innovation leadership in transforming patient access through omnichannel, AI-powered engagement and workflow unification.

SAN ANTONIO, March 2, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that Innovaccer has received the 2026 United States New Product Innovation Recognition in the United States Patient Access Solutions Industry for its outstanding achievements in innovation, strategy execution, and customer impact. This recognition highlights Innovaccer's consistent leadership in modernizing patient access through AI-driven, omnichannel engagement, strengthening its market position, and delivering customer-centric innovation in an increasingly competitive healthcare landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. Innovaccer excelled in both, demonstrating its ability to align strategic initiatives with evolving market demand while executing them with efficiency, consistency, and scale. "Frost & Sullivan recognizes Innovaccer for its innovative approach to patient access and engagement, highlighting its ability to unify fragmented workflows and deliver a truly omnichannel, AI-driven experience. The company's Comet AI platform, a combination of autonomous AI agents and intelligent copilots, enhances operational efficiency, improves patient satisfaction, and boosts staff productivity," said Alejandra Parra, Research Analyst at Frost & Sullivan.

Guided by a long-term growth strategy focused on digital innovation, data integration, and customer-centric partnerships, Innovaccer has demonstrated strong strategic agility in addressing critical gaps across the patient access value chain. The company's sustained investment in artificial intelligence, automation, and healthcare interoperability has enabled it to scale effectively across the United States healthcare market, helping providers compress complex workflows and deliver more seamless care experiences.

Innovation remains central to Innovaccer's approach. Comet AI, the company's patient access and engagement platform transforms traditional call centers into intelligent, always-on digital front doors that operate across voice, chat, SMS, and web channels. By unifying electronic medical records, scheduling, referral management, and communication tools into a single pane of glass, Comet AI enables healthcare staff to manage up to 70% to 80% of routine interactions autonomously while reserving human expertise for more complex cases.

"Patient access is where healthcare systems feel the most pressure, high volumes, fragmented workflows, and rising expectations from patients," said Abhinav Shashank, cofounder and CEO of Innovaccer. "Comet AI was built to address this reality by autonomously handling routine interactions across channels, unifying access workflows, and helping care teams operate with far greater speed and clarity. This recognition from Frost & Sullivan reinforces our belief that autonomous, AI-driven patient access is not a future concept and it is already delivering measurable impact for healthcare organizations today."

Innovaccer's unwavering commitment to customer experience further strengthens its leadership in the patient access solutions market. The platform streamlines service delivery, enables self-service through intuitive digital channels, and maintains high levels of reliability and availability. AI copilots support live agents with next-best-action recommendations, real-time documentation, and insurance or eligibility verification, improving productivity while reducing burnout. This integrated, omnichannel model delivers measurable outcomes, including improved appointment bookings, reduced referral leakage, higher patient satisfaction, and demonstrable return on investment for healthcare organizations.

Frost & Sullivan commends Innovaccer for setting a high standard in competitive strategy, execution, and market responsiveness. The company's innovation pipeline, AI-driven vision, and patient-first culture are shaping the future of the United States patient access solutions industry and driving tangible results at scale.

Each year, Frost & Sullivan presents the New Product Innovation Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The accolade recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Lindsey Whitaker
Lindsey.Whitaker@Frost.com

About Innovaccer

Innovaccer is the AI infrastructure for autonomous healthcare operations, delivering better clinical and financial outcomes across health systems, payers, governments, and life sciences. Powered by the Healthcare Intelligence Platform, Innovaccer unifies enterprise data and applies AI to automate administrative work, strengthen operational performance, and drive measurable margin expansion. Organizations such as Orlando Health, Adventist HealthCare, and Banner Health trust Innovaccer to integrate intelligence into their existing infrastructure and elevate the quality of care. For more information, visit www.innovaccer.com.

Press Contact:
Arushi Awasthi
Innovaccer Inc.
arushi.awasthi@innovaccer.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/innovaccer-receives-frost--sullivans-2026-united-states-new-product-innovation-recognition-for-excellence-in-ai-driven-patient-access-solutions-302701249.html

© 2026 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.